Patients have access to: Licensed U.S.-based physicians Injectable and oral GLP-1 options Ongoing provider support Flexible treatment approaches No insurance requirements Convenient home delivery The focus is always on safe, medically appropriate care tailored to the individual
The key question will be long-term durability, safety, tolerability, and how these therapies perform in broader real-world populations beyond controlled trials
If you experience severe abdominal pain, signs of pancreatitis, or persistent nausea, contact your healthcare provider immediately
In March 2026, the FDA approved Wegovy HD (7.2 mg) specifically for "non-responders" or those who hit a plateau
Rights and permissions About this article Cite this article Moura, F.A., Scirica, B.M
doi: 10.1080/07853890.2017.1306653 41 BaggioLLYustaBMulvihillEECaoXStreutkerCJButanyJet al